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OBJECTIVE — The A1C assay, expressed as the percent of hemoglobin that is glycated,
measures chronic glycemia and is widely used to judge the adequacy of diabetes treatment and
adjust therapy. Day-to-day management is guided by self-monitoring of capillary glucose con-
centrations (milligrams per deciliter or millimoles per liter). We sought to deﬁne the mathemat-
ical relationship between A1C and average glucose (AG) levels and determine whether A1C
could be expressed and reported as AG in the same units as used in self-monitoring.
RESEARCH DESIGN AND METHODS — A total of 507 subjects, including 268 pa-
tients with type 1 diabetes, 159 with type 2 diabetes, and 80 nondiabetic subjects from 10
international centers, was included in the analyses. A1C levels obtained at the end of 3 months
and measured in a central laboratory were compared with the AG levels during the previous 3
months. AG was calculated by combining weighted results from at least 2 days of continuous
glucose monitoring performed four times, with seven-point daily self-monitoring of capillary
(ﬁngerstick) glucose performed at least 3 days per week.
RESULTS — Approximately 2,700 glucose values were obtained by each subject during 3
months. Linear regression analysis between the A1C and AG values provided the tightest cor-
relations (AGmg/dl  28.7  A1C  46.7, R
2  0.84, P  0.0001), allowing calculation of an
estimated average glucose (eAG) for A1C values. The linear regression equations did not differ
signiﬁcantlyacrosssubgroupsbasedonage,sex,diabetestype,race/ethnicity,orsmokingstatus.
CONCLUSIONS — A1C levels can be expressed as eAG for most patients with type 1 and
type 2 diabetes.
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T
heA1Cassayiswidelyacceptedand
used as the most reliable means of
assessingchronicglycemia(1–3).Its
close association with risk for long-term
complications, established in epidemio-
logic studies and clinical trials (4–6), has
lead to the establishment of speciﬁc A1C
targets for diabetes care with the goal of
preventing or delaying the development
of long-term complications (2,7–9). Dia-
betes treatment is adjusted based on the
A1C results, expressed as the percentage
of hemoglobin that is glycated. The vast
majorityofassayshavebeenstandardized
worldwide, through the National Glyco-
hemoglobin Standardization Program
(10), to the assay used in the Diabetes
Control and Complications Trial
(DCCT), which established the relation-
shipbetweenA1Clevelsandriskforlong-
term diabetes complications (4,5).
A new, more stable and speciﬁc
method of standardization of the A1C as-
say, which is not intended for use in rou-
tine assays, has been developed and
proposed to be used for global standard-
ization by the International Federation of
Clinical Chemists (11,12). However, the
newmethodresultsinvaluesthatare1.5–
2.0 percentage points lower than current
National Glycohemoglobin Standardiza-
tion Program values (13), potentially
causing confusion for patients and health
care providers. Moreover, the Interna-
tional Federation of Clinical Chemists re-
sults would be expressed in new units
(millimoles per mole), which would add
totheconfusion.Chronicglycemia(A1C)
isusuallyexpressedasapercentageofhe-
moglobin that is glycated, whereas the
day-to-day monitoring and therapy of di-
abetes are based on acute glucose levels
expressed as milligrams per deciliter or
millimoles per liter. This discrepancy
has always been problematic. If we
could reliably report chronic metabolic
control and long-term management
goals as average glucose (AG), i.e., in
the same units of measurement as acute
glycemia, it would eliminate these po-
tential sources of confusion.
The relationship between A1C and
chronic glycemia has been explored in
several studies that have supported the
associationofA1CwithAGlevelsoverthe
preceding 5–12 weeks (14–21). How-
ever, the older studies have been limited,
including relatively small homogeneous
cohorts of patients, usually with type 1
diabetes (14–19). Moreover, almost all of
thepriorstudieshavereliedoninfrequent
measures of capillary glucose levels, call-
ing into question the validity of their as-
sessment of chronic glycemia. We
performed an international multicenter
study to examine the relationship be-
tween average glucose, assessed as com-
pletely as possible with a combination of
continuous glucose monitoring and fre-
quent ﬁngerstick capillary glucose test-
ing, and A1C levels over time to estimate
the relationship between the two.
RESEARCH DESIGN AND
METHODS— Study subjects were re-
cruited at 11 centers in the U.S., Europe,
Africa, and Asia according to the consen-
sus protocol. Type 1 and type 2 diabetic
andnondiabeticvolunteerswerebetween
the ages of 18 and 70 years and were
judgedaslikelytobeabletocompletethe
protocol, including performance of the
self-monitoringbyﬁngerstickandcontin-
uous glucose monitoring. To be eligible,
nondiabetic subjects had to have no his-
tory of diabetes, a plasma glucose level
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night fast, and an A1C level 6.5%. The
diabetic subjects had to have stable glyce-
mic control as evidenced by two A1C val-
ues within 1 percentage point of each
other in the 6 months before recruitment.
Any conditions that might result in a ma-
jor change in glycemia, such as diseases
that might require steroid therapy or
plans for pregnancy during the study pe-
riod, were exclusionary. Similarly, any
conditions or treatments that might inter-
fere with the measurement of A1C by any
ofthestudymethods,suchashemoglobi-
nopathies (22), or that might interfere
with the putative relationship between
A1C and AG values, including anemia
(hematocrit 39% in men and 36% in
women), high erythrocyte turnover as ev-
idenced by reticulocytosis, blood loss
and/or transfusions, chronic renal or liver
disease, or high-dose vitamin C or eryth-
ropoetin treatment, were grounds for ex-
clusion. The study was approved by the
human studies committees at the partici-
pating institutions, and informed consent
was obtained from all participants.
Measures of glycemia
Measures of glycemia included continu-
ousinterstitialglucosemonitoring(CGM)
(CGMS; Medtronic Minimed, North-
ridge,CA),whichmeasuresglucoselevels
every5minandwasperformedforatleast
2 days at baseline and then every 4 weeks
during the next 12 weeks. For calibration
purposes and as an independent measure
of glycemia, subjects performed eight-
point(premeal,90minpostmeal,prebed,
andat3:00 A.M.)self-monitoringofcap-
illary glucose with the HemoCue blood
glucose meter (Hemocue Glucose 201
Plus; Hemocue, A ´ ngelholm, Sweden)
during the 2 days of CGM. As a third
and independent measure of glycemia,
subjects were asked to perform seven-
point (same as the eight-point proﬁle
above without the 3:00 A.M. measure-
ment) ﬁngerstick capillary glucose
monitoring (OneTouch Ultra; Lifescan,
Milipitas, CA) for at least 3 days per
week,attimeswhenCGMwasnotbeing
performed, for the duration of the
study. The results from the CGM and
ﬁngerstick monitoring were down-
loaded from their respective meters and
exported to the data coordinating cen-
ter. To be acceptable for analysis, the
CGM data had to include at least one
successful 24-h proﬁle out of the 2–3
days of monitoring with no gaps 120
min and a mean absolute difference
compared with the Hemocue calibra-
tion results 18%, as recommended by
the manufacturer.
BloodsamplesforA1Cwereobtained
at baseline and monthly for 3 months.
Thebloodsampleswerefrozenat80°C
and were sent on dry ice by overnight
shipment to the central laboratory. Sam-
ples were analyzed with four different
DCCT-aligned assays, including a high-
performance liquid chromatography as-
say (Tosoh G7; Tosoh Bioscience, Tokyo,
Japan), two immunoassays (Roche A1C
and Roche Tina-quant; Roche Diagnos-
tics), and an afﬁnity assay (Primus Ul-
tra-2; Primus Diagnostics, Kansas City,
MO). The mean A1C value was used. The
laboratory assays were approved by the
National Glycohemoglobin Study Pro-
gram (10) and have intra- and interassay
coefﬁcients of variation 2.5% for low
and high values. The assays were highly
intercorrelated with R
2 values of 0.99 and
slopes of 1.0 and intercepts between
0.01 and 0.18. Any samples that demon-
strated “aging peaks” on high-perfor-
mance liquid chromatography, evidence
of degradation during storage and/or
shipment, were considered unacceptable
for analysis. One center in Asia was un-
abletostoresamplesacceptably,resulting
in samples that could not be assayed for
A1C. The center was eliminated from the
study.
Diabetes management
The study was observational in design.
Diabetes management was left to the pa-
tients and their usual health care provid-
ers and was adjusted based on their
ﬁngerstick self-monitoring results. CGM
results were reviewed by the study staff at
the time they were downloaded. Partici-
pants were usually masked to the CGM
results during the study; unmasking was
requiredifotherwiseundetectedfrequent
or prolonged periods of hypoglycemia
were observed, in which case, the health
care provider was alerted so that treat-
ment could be adjusted.
Statistical analysis
Wecalculatedanarithmeticmeanglucose
(AG) for each subject by combining the
CGM measurement of interstitial glucose
levels, corrected by a factor of 1.05 to be
equivalent to capillary glucose levels in
our study, and the Lifescan ﬁngerstick
measurements of capillary glucose. Be-
causeglucoselevelsweremeasuredmuch
more frequently on the CGM days (n 
288 per day) than during the Lifescan
days(n7),theresultswereweightedso
that each measurement was proportional
to the inverse of the total number of mea-
surements taken in the same day. There-
fore, equal weight was attached to each
day during which glucose levels were
measured. Subjects with fewer than 7
days of CGM during the study were ex-
cluded from analysis. We applied linear
and quadratic regression models to esti-
mate the relationship between A1C and
AG. The quadratic model did not provide
a signiﬁcant improvement over the linear
regression model (P  0.82). An expo-
nential model was considered but not
used, since the paucity of data in the
higher A1C range led to highly variable
estimates.Predictionintervalswerecalcu-
lated to represent the range of predicted
AG at given A1C levels (23). To correct
for heteroschedasticity, we ﬁt a model
where the variance of AG is an increas-
ing function of A1C. As a result, the
90% prediction intervals for AG given
A1C is given by
a  b  A1C  tn1,1a/2
 1 
1
n1	A1C

2/2,
where n  507 and 0.1, which leads
to tn1,1/2  1.648 and 1 
1
m  1.
The mathematical details of the
Bayesian method are given in online ap-
pendix 1, available at http://dx.doi.org/
10.2337/dc08-0545.
For the overall study results to be
considered acceptable, it was decided a
priori that 90% of the individual pa-
tients’ calculated AG would have to fall
within 15% of the study-wide calcu-
lated AG.
We examined the inﬂuence of factors
such as age, sex, race (Caucasian, African
or African American, or Hispanic), and
smoking history on the relationship be-
tweenA1CandAGthroughamultivariate
regression model. We compared the
slopes and intercepts of the regression
equations for the individual subgroups
and calculated the SDs of the prediction
error for each. Age was divided by tertiles
separately for type 1 (40, 40–50, 50
years) and type 2 diabetes (50, 50–60,
60 years).
RESULTS— Between April 2006 and
August 2007, 661 patients were recruited
from10clinicalcenters:6intheU.S.,3in
Europe, and 1 in Cameroon. A total of
A1C assay and estimated average glucose values
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had type 2 diabetes, and 90 were non-
diabetic (Table 1). The participants were
distributed by baseline A1C in three
groups,with18%withA1C8.5%,44%
between 6.6 and 8.5%, and 38% between
4 and 6.5%. The lowest A1C group con-
sisted of 63% diabetic patients and 37%
nondiabetic participants.
Of 661 subjects who completed
screening visits, 154 (23%) were not in-
cludedintheﬁnalanalysesforthefollow-
ing reasons: 91 (15%) did not complete
the study or were excluded before study
end because of conditions that were pre-
deﬁned(suchassicklecelltrait[n5]or
anemia [n  5]), were identiﬁed during
screening,ordevelopedduringthestudy;
11(2%)didnothaveadequateCGM;and
52 (8%) did not have samples that could
be evaluated for A1C for technical rea-
sons, including sample degradation be-
cause of storage or shipment problems.
A total of 507 subjects completed the
studyandhadadequateglucose-monitor-
ingandA1Csamplestobeincludedinthe
analyses (Table 1). The CGM and the
Lifescan ﬁngerstick capillary-monitoring
data included 2,500 and 230 measure-
ments per subject, respectively, for a total
of 2,700 glucose tests during the
3-monthperiod.Themediannumberof
days of CGM was 13 and of ﬁngerstick
capillarymonitoringwas39;36%ofthe
seven-point proﬁles were complete,
withthemeannumberoftestsbeing5.1
perday.ThecorrelationoftheCGMand
simultaneous Hemocue measurements
not used for calibrating CGM was excel-
lent, with the 95% limit of the overall
average CGMS minus average Hemocue
equaling 30.6 to 30.6 mg/dl (1.7 to
1.7 mmol/l).
For measuring the steady-state corre-
lation between AG and A1C, the study
was designed to include subjects with rel-
atively stable glycemia. A1C values were
generally stable, with 96% of the subjects
maintaining A1C within 1 percentage
point of their baseline value over the
course of the study.
The relationship between the A1C
level at the end of the 3-month study pe-
riod and the calculated AG during the
preceding 3 months, expressed as the
simple linear regression AGmg/dl 
28.7  A1C – 46.7 (AGmmol/l  1.59 
A1C  2.59), R
2  0.84, P  0.0001, is
showninFig.1.ThecorrelationhasanSD
of prediction error of 15.7 mg/dl (0.87
mmol/l).Basedonthemodeldescribedin
the statistical analysis section, the esti-
mated values are as follows:  41.4,
95%CI48.8to33.5;27.9,26.7–
29.0;14.81,2.18–15.33;22.03,
1.42–2.59. This leads to an estimated er-
ror SD of 13.4, 15.7, and 18.0 mg/dl
when A1C is 6, 7, and 8%, respectively.
The Bayesian model–suggested regres-
sion line differs 2 mg/dl from a simple
linear regression line in the A1C range of
4–10%, which includes 98.5% of our
samples; the prediction intervals widen
(P0.05)asA1Cvaluesincreaseto12%,
but the difference between the Bayesian
and simple linear regression is still 5
mg/dl. A Bland-Altman type of analysis
examining the difference between the es-
timated glucose and observed glucose
over the range of glucose values is shown
inonlineappendix2.The90%prediction
limitsfortheAG,basedonthevaryingSD
model,wereveryclosetothepresetlimits
of 15% of the predicted mean over the
full range of A1C; 89.95% of the samples
fell within 15% of the calculated AG.
The translation of A1C to estimated
AG(eAG)basedonthelinearregressionis
showninTable2,forconventionalandSI
units,andwiththe95%predictionlimits.
Of note, the regression equation for A1C
and AG using only the CGM results to
calculate AG was AGCGM  28.0 
A1C36.9(R
20.82,P0.0001);the
regression using only the seven-point ﬁn-
gerstick proﬁles to calculate AG was AG7-
POINT  29.1  A1C  50.7 (R
2  0.82,
P0.0001).Thedifferenceintheregres-
sions was not statistically signiﬁcant for
slopeandinterceptcombined(P0.11).
The relationship between A1C and
AG was the same when only the diabetic
subjects were included (linear regression
eAG  28.3  A1C  43.9 [R
2  0.79,
P0.0001])asthatforthewholecohort.
A comparison of the regression equations
within the speciﬁed subgroups is shown
in Table 3. There were no signiﬁcant dif-
Table 1—Baseline characteristics
Screened cohort Analyzed subjects
Type 1 Type 2 Nondiabetic All Type 1 Type 2 Nondiabetic All
n 335 236 90 661 268 159 80 507
Age 42  13.1 54  9.4 38  13.1 46.1  13.5 43  13 56  94 0  14 46  14
Sex (% female) 171 (51) 119 (50) 60 (67) 350 (53) 140 (52) 81 (51) 55 (69) 276 (54)
Race/ethnicity
Non-Hispanic white 282 (84) 145 (61) 60 (67) 487 (74) 248 (93) 118 (73) 56 (71) 422 (83)
African/African American 23 (7) 59 (25) 15 (17) 97 (15) 5 (2) 21 (13) 12 (15) 38 (8)
Hispanic 18 (5) 23 (10) 15 (17) 56 (8) 15 (6) 12 (8) 12 (15) 39 (8)
Other 12 (4) 9 (4) 0 21 (3) 0 8 (5) 0 8 (2)
Smoking status 40 (12) 29 (12) 7 (8) 76 (12) 32 (12) 14 (9) 7 (9) 53 (11)
A1C (%) 7.3  1.1 6.7  0.9 5.3  0.3 6.8  1.2 7.3  1.1 6.8  1.1 5.2  0.3 6.8  1.3
Treatment
External pump 42% 47%
Three or more daily
injections
58% 53%
Diet only 12% 10%
Oral agent(s) only 54% 52%
Insulin only 17% 19%
Insulin  oral agent(s) 17% 19%
Data are means  SD or n (%) unless otherwise indicated.
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regression equations for any of the sub-
group comparisons, and the SDs of the
prediction error were all close to the 15.7
mg/dl (0.87 mmol/l) value for the entire
study cohort.
CONCLUSIONS — Theresultsofthe
A1c-Derived Average Glucose (ADAG)
study support the notion of a close rela-
tionship between A1C levels and AG for
both type 1 and type 2 diabetes. The A1C
assay plays a central role in the clinical
management of diabetes. Treatment goals
designed to reduce the development of
long-term complications were adopted in
the wake of the DCCT (4), and A1C assay
methods have been standardized to the
DCCT values in most of the world (10). A
newlydevelopedmethodofassaycalibra-
tion, which is more stable and speciﬁc,
shouldfurtherimprovethecomparability
of assays worldwide (11,12). Since this
method measures a well-deﬁned analyte
of only one molecular species of glycated
hemoglobin, the reference values are
lower, compared with the previous
DCCT-alignedassays.Toavoidconfusion
and potential deterioration of glycemic
control as a result of having to report
lower A1C values (24), the current study
set out to determine the relationship be-
tweenA1CandAG.Theultimateaimwas
to determine whether the A1C index of
chronicglycemiacouldbereportedinthe
same units as used for day-to-day moni-
toring (12,25).
Previous studies of the relationship
between A1C and average glycemia have
generally been hampered by limited mea-
surements of glucose values, casting
doubt on the reliability of the estimates of
AG. CGM provides the opportunity to
measure all glucose levels. A recent study
that included CGM for 3 months arrived
at a relationship between A1C and AG
very similar to that presented here, pro-
viding external validation, but included
only 25 subjects, most of whom had type
1 diabetes (21). The current study pro-
vides a relatively complete assessment of
day-to-day glycemia and establishes a
strong enough relationship between A1C
andAGlevelstojustifyadirecttranslation
from measured A1C to an easier-to-
understand value that is in the same units
as ﬁngerstick monitoring. Of note, the re-
gression equation in this study provides
lower eAG values, compared with the
widely used equation derived from the
DCCT, and the scatter around the regres-
sion line is less wide (18). The most obvi-
ous explanation for the difference
between AG calculated from the DCCT
and that calculated in the current study is
the difference in the frequency of glucose
measurements used to calculate AG (a
single seven-point proﬁle with no over-
night measurements during 3 months in
the DCCT compared with numerous
CGM and seven-point proﬁle measure-
ments that captured a median of 52 days
in ADAG), providing a more complete
and representative measure of average
glucose in ADAG.
Our results strongly support a simple
linear relationship between mean glucose
and A1C levels in a clinically relevant
range of glycemia. Our data fulﬁlled the a
priori quality criterion; i.e., 90% of the
Figure 1—Linear regression of A1C at the end of month 3 and calculated AG during the preceding 3 months. Calculated AGmg/dl  28.7  A1C 
46.7 (AGmmol  1.59  A1C  2.59) (R
2  0.84, P  0.0001).
Table 2—Estimated average glucose
mg/dl* mmol/l†
A1C (%)
5 97 (76–120) 5.4 (4.2–6.7)
6 126 (100–152) 7.0 (5.5–8.5)
7 154 (123–185) 8.6 (6.8–10.3)
8 183 (147–217) 10.2 (8.1–12.1)
9 212 (170–249) 11.8 (9.4–13.9)
10 240 (193–282) 13.4 (10.7–15.7)
11 269 (217–314) 14.9 (12.0–17.5)
12 298 (240–347) 16.5 (13.3–19.3)
Data in parentheses are 95% CIs. *Linear regression
eAG (mg/dl)  28.7  A1C  46.7. †Linear regres-
sion eAG (mmol/l)  1.5944  A1C  2.594.
A1C assay and estimated average glucose values
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the regression line. This criterion was
considered realistic, allowing for the im-
precision of the A1C assay, CGM, and
self-monitored blood glucose tests.
The large population allowed us to
demonstrate that the relationship be-
tween A1C and AG was consistent across
prespeciﬁed subgroups. The tight rela-
tionship and the consistency of the rela-
tionship across different subgroups
suggest that for many, if not most, pa-
tients with diabetes, there are no impor-
tant factors that affect the relationship
between mean glucose levels and A1C.
There was a suggestion (P  0.07) that
the regression line was different for Afri-
can Americans such that for a given value
of A1C, African Americans might have a
slightly lower mean glucose level. This
borderlineresultrequiresfurtherstudyto
be conﬁdent that there is no relationship
between ethnicity and the relationship
between mean glucose and A1C. There
was also a suggestion that age may affect
the relationship between AG and A1C;
however, the effect was not monotonic.
The regression lines for each age-group
crossed at A1C of 7%, with the ﬁrst and
last tertile being similar and the middle
tertile being different. We suspect that
this is a spurious ﬁnding. There are other
well-recognized clinical factors, such as
anemia and altered erythrocyte turnover,
which can affect A1C results measured
with all assay methods, and hemoglobi-
nopathies, which interfere with the mea-
surement of A1C with speciﬁc methods
(22). Potential subjects with these condi-
tions were excluded from the study.
The ADAG study has a few limita-
tions. In contrast to our intention and ex-
pectation,someethnic/racialgroupswere
underrepresented, primarily because of
the withdrawal of one of the centers with
a large Asian population and a limited
number of subjects of African descent. In
addition, the average glucose estimation
was based predominantly on two meth-
ods: CGM and intermittent self-
monitoring of capillary glucose. (The
Hemocue measurements, recognized as
providing values that are equivalent to
laboratory measurements, were used pri-
marily to calibrate the CGM [26].) To
combine these measurements into a sin-
gle calculated AG, the CGM and ﬁnger-
stick capillary measurements had to be
weighted to take into account the differ-
ent number of measurements in a day;
however, in separate analyses comparing
the relationships between A1C and AG
measured with CGM or ﬁngerstick capil-
lary measurements, there was no signiﬁ-
cant difference in the relationships.
Finally,sinceonlydiabeticpatientsinsta-
ble control and without any suggestion of
erythrocyte disorders were entered into
the study, the current results are only di-
rectly applicable to this population. Chil-
dren and pregnant women were also
excluded; additional data in these groups
are needed to conﬁrm the established re-
lationship. Of note, a recently published
study compared the calculated mean
glucose of 47 children with type 1 dia-
betes between the ages of 4 and 18 years
who had at least one 24-h period of
CGM in 6 of 13 weeks with the A1C at
the end of the 13-week period (27). Al-
though the authors also concluded that
“A1C directly reﬂects mean glucose
over time,” they found substantially
greater inter-individual variation in the
relationship between AG and A1C than
presentinthecurrentstudy.Thepoten-
tial sources of this variability can be
identiﬁed by comparing the DirectNet
study in children (27) with ADAG and
withtherecentstudyinadults(21)who
were selected for stable glycemic con-
trol and performed CGM for 97% of the
12-week study period. The DirectNet
study used a noncentralized A1C
method with relatively poor correlation
with a high-performance liquid chro-
matography method. Moreover, the
children had highly variable glycemia
and only performed CGM for 67% of
the study period; this may have failed to
accurately capture mean glycemia.
The current results support the re-
porting of the measured A1C as eAG. The
interpretation of the A1C, analogous to
reporting serum creatinine as a calculated
glomerular ﬁltration rate, should provide
health care providers with a more useful
index of chronic glycemia. A recently
published consensus guideline has en-
dorsed reporting A1C values along with
the calculated eAG level, assuming that
the results of the ADAG were acceptable
(25).
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Table 3—Comparison of regression equations between A1C and AG for subgroups
Comparison
Difference in
slope
Difference in
intercept P*
Sex Male vs. female 0.17  1.14 0.57  7.94 0.91
Diabetes type Type 1 vs. type 2 1.46  1.61 9.35  11.21 0.41
Age, type 1 diabetes 1st vs. 2nd tertile 1.03  2.27 5.61  16.56 0.71
1st vs. 3rd tertile 1.53  2.37 6.99  17.59 0.18
2nd vs. 3rd tertile 0.50  2.47 1.38  18.29 0.69
Age, type 2 diabetes 1st vs. 2nd tertile 7.40  3.67 52.00  24.43 0.08
1st vs. 3rd tertile 1.57  3.36 11.59  22.31 0.84
2nd vs. 3rd tertile 5.83  3.07 40.41  21.45 0.17
Ethnicity Caucasian vs. African/African-American 3.87  1.85 23.35  12.48 0.07
Caucasian vs. Hispanic 1.80  3.12 5.89  20.51 0.81
Hispanic vs. African/African-American 2.06  3.49 17.46  22.94 0.43
Smoking Never vs. current 2.62  1.48 16.76  10.93 0.14
Data are means  SE. *

2 test with 2 d.f. comparing the intercept and slope simultaneously.
Nathan and Associates
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ADAG Study Group
Study centers: J.K. (principle investigator
[PI]), G.S.M.A Kerner, and A. van Iperen,
Amsterdam, the Netherlands; E. Horton
(PI), A. Cohen, S. Herzlinger-Botein, and
J. Paradis, Boston, MA; C. Saudek (PI), K.
Moore, A. Greene, and M. Islas, Balti-
more, MD; J. Nerup (PI), R.B., and C.
Glu ¨mer, Copenhagen, Denmark; A.
Mosca (co-PI), A. Lapolla (co-PI), D.
Fedele, and G. Sartore, Padova, Italy; X.
Pi-Sunyer (PI), C. Maggio, L. Haselman,
and C. Bellino, New York, NY; S. Smith
(PI), A. Reynolds, T. Robertson, H. Bin-
ner, and K. Hurtis, Rochester, MN; S.
Schwartz (PI), A. Ramos, A. Gonzales, A.
Childress, and Y. Martinez, San Antonio,
TX; I. Hirsch (PI), D. Khakpour, and C.
Farricker, Seattle, WA; and J.C. Mbanya
(PI), E. Sobngwi, and E. Balti, Yaounde ´,
Cameroon.Centrallaboratory:R.Slinger-
land (PI), E. Lenters, and H.P van Berkel,
Zwolle, the Netherlands. Biostatistics
center: D.S. (PI), H.Z., K. Pelak, and R.
Wilson, Boston, MA. Coordinating cen-
ter: D.M.N. (PI), N. Kingori, and H. Tur-
geon, Boston, MA. Study chairs: R.H. and
D.M.N.
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